A randomized, two-way crossover study of the effects of a single dose of rabeprazole or pantoprazole on 24-hours intragastric acidity and esophageal acid exposure in GERD [gastro-esophageal reflux disease] patients with a history of nocturnal heartburn

Trial Profile

A randomized, two-way crossover study of the effects of a single dose of rabeprazole or pantoprazole on 24-hours intragastric acidity and esophageal acid exposure in GERD [gastro-esophageal reflux disease] patients with a history of nocturnal heartburn

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2010

At a glance

  • Drugs Pantoprazole; Rabeprazole
  • Indications Gastro-oesophageal reflux; Heartburn
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Feb 2010 Primary endpoint 'Time with intragastric pH greater than 4' has been met.
    • 18 Aug 2009 Actual patient number (52) added as reported by ClinicalTrials.gov.
    • 19 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top